...
首页> 外文期刊>Japanese Journal of Ophthalmology >Additional reduction in intraocular pressure achieved with latanoprost in normal-tension glaucoma patients previously treated with unoprostone.
【24h】

Additional reduction in intraocular pressure achieved with latanoprost in normal-tension glaucoma patients previously treated with unoprostone.

机译:拉坦前列素在以前接受过unoprostone治疗的正常血压青光眼患者中可进一步降低眼内压。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: To determine whether treatment with latanoprost eye drops is able to further reduce intraocular pressure (IOP) in normal-tension glaucoma (NTG) patients whose IOP has been well controlled with unoprostone. PATIENTS AND METHODS: A total of 34 eyes (34 individuals) with NTG that had been treated with 0.12% unoprostone eye drops twice daily for >or=3 months were switched to treatment once daily with eye drops containing 0.005% latanoprost. IOP was measured before and 1, 2, and 3 months after the switch to latanoprost. RESULTS: The mean IOP of all eyes was decreased significantly by 1.8, 2.9, and 2.3 mmHg at 1, 2, and 3 months after the switch from unoprostone to latanoprost treatment. The IOP of patients with an initial IOP of 12 mmHg was reduced by 11.0 or 19.9%, respectively, after 3 months on latanoprost. The IOP of 30 (88.2%) of the 34 eyes was further reduced by the switch from unoprostone to latanoprost. CONCLUSIONS: Latanoprost reduced the IOP of NTG patients who had already been treated with unoprostone, even though both drugs are prostaglandin-related. Switching to latanoprost might thus achieve a maximal decrease in IOP and thereby better prevent damage to the optic nerve and loss of visual field in NTG patients.
机译:目的:确定用拉诺前列素滴眼液治疗是否能够进一步降低已用unoprostone很好控制了眼压的正常血压青光眼(NTG)患者的眼内压(IOP)。患者和方法:每天用0.12%unoprostone滴眼液治疗两次或以上= 3个月,共34眼NTG眼(34例)改为每天使用含0.005%拉坦前列素的眼药水治疗。在转用拉坦前列素之前,1、2和3个月测量了IOP。结果:从unoprostone改为latanoprost治疗后1、2和3个月,所有眼睛的平均IOP分别显着降低了1.8、2.9和2.3 mmHg。接受拉坦前列素治疗3个月后,初始IOP≤12或> 12 mmHg的患者的IOP分别降低了11.0或19.9%。从unoprostone改为latanoprost,进一步降低了34只眼中30只眼的IOP(88.2%)。结论:拉坦前列素降低了已经用unoprostone治疗的NTG患者的IOP,即使这两种药物均与前列腺素有关。因此,改用拉坦前列素可能会最大程度地降低IOP,从而更好地防止NTG患者的视神经受损和视野丧失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号